According to clinical guidelines for recurrence, ATSR was established as follows: the molecular target drug for EGFR from 2006, for ALK from 2007, for BRAF from 2014, for ROS1 from 2016, for an immune checkpoint inhibitor from 2017, for tumour proportion score (TMS) ≥ 50% of program cell death protein 1 (PD-1). This evidence concerns the gene EGFR and neoplasm.